Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma.
Guoqiang SunGanggang MiaoZhitao LiWubin ZhengChunguang ZhouGuangshun SunHongyong CaoZhouxiao LiWeiwei TangPublished in: Journal of oncology (2022)
The present study reveals that inhibition of PARP potentiates immune checkpoint therapy through the miR-513/PD-L1 pathway in HCC and the combination of PARP inhibitor olaparib and anti-PD1 is beneficial to HCC therapy.